Not all depression is created equal: Sex interacts with disease to precipitate depression

Biology of Sex Differences

Volumn 4, Issue 1, 2013, Pages

  Nemeth, Christina L ^a   Harrell, Constance S ^a   Beck, Kevin D ^b,c   Neigh, Gretchen N ^a,d  

^a EMORY UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's; Cancer; Cardiovascular; Depression; Epilepsy; Sex difference

Indexed keywords

EID: 84888122739     PISSN: None     EISSN: 20426410     Source Type: Journal    
DOI: 10.1186/2042-6410-4-8     Document Type: Review

References (113)

1. WHO: The Global Burden of Disease. 2004 Update. Geneva: World Health Organization; 2008.
2. Pagura J, Cox BJ, Sareen J, Enns MW: Factors associated with multiple versus single episode suicide attempts in the 1990-1992 and 2001-2003 United States national comorbidity surveys. J Nerv Ment Dis 2008, 196:806-813.
3. Rockett IR, Regier MD, Kapusta ND, Coben JH, Miller TR, Hanzlick RL, Todd KH, Sattin RW, Kennedy LW, Kleinig J, Smith GS: Leading causes of unintentional and intentional injury mortality: united states, 2000-2009. Am J Public Health 2012, 102:e84-e92.
4. Steiner M, Dunn E, Born L: Hormones and mood: from menarche to menopause and beyond. J Affect Disord 2003, 74:67-83. (Pubitemid 36324478)
5. Piccinelli M, Wilkinson G: Gender differences in depression. Critical review. Br J Psychiatry 2000, 177:486-492. (Pubitemid 32005477)
6. Naninck EF, Lucassen PJ, Bakker J: Sex differences in adolescent depression: do sex hormones determine vulnerability? J Neuroendocrinol 2011, 23:383-392.
7. Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z: Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 2009, 159:1216-1232.
8. Pinkerton JV, Guico-Pabia CJ, Taylor HS: Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol 2010, 202:221-231.
9. Kanner AM: Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 2003, 54:388-398. (Pubitemid 37267865)
10. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH: Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005, 57:381-387. (Pubitemid 40343960)
11. Massie MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004, 2004:57-71.
12. Shanmugasegaram S, Russell KL, Kovacs AH, Stewart DE, Grace SL: Gender and sex differences in prevalence of major depression in coronary artery disease patients: A meta-analysis. Maturitas 2012, 73:305-311.
13. Gilliam FG, Santos J, Vahle V, Carter J, Brown K, Hecimovic H: Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia 2004, 45(Suppl 2):28-33. (Pubitemid 38856388)
14. Kanner AM: Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol 2012, 11:1093-1102.
15. Epilepsy Fast Facts. http://www.cdc.gov/epilepsy/basics/fast-facts.htm.
16. Ropper A, Samuels M: Epilepsy and Other Seizure Disorders. In Adams and Victor's Principles of Neurology. 9th edition. New York: McGraw-Hill; 2009.
17. Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA: Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002, 43:1402-1409. (Pubitemid 35365000)
18. Mula M: Epilepsy: Bidirectional link between epilepsy and psychiatric disorders. Nat Rev Neurol 2012, 8:252-253.
19. Barraclough BM: The suicide rate of epilepsy. Acta Psychiatr Scand 1987, 76:339-345.
20. Altshuler LL, Devinsky O, Post RM, Theodore W: Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms. Arch Neurol 1990, 47:284-288. (Pubitemid 20098692)
21. Piazzini A, Canevini MP, Maggiori G, Canger R: Depression and anxiety in patients with epilepsy. Epilepsy Behav 2001, 2:481-489. (Pubitemid 33585806)
22. Strauss E, Wada J, Moll A: Depression in male and female subjects with complex partial seizures. Arch Neurol 1992, 49:391-392.
23. Kohler C, Norstrand JA, Baltuch G, O'Connor MJ, Gur RE, French JA, Sperling MR: Depression in temporal lobe epilepsy before epilepsy surgery. Epilepsia 1999, 40:336-340. (Pubitemid 29164799)
24. Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R: Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
25. Sarkisova K, van Luijtelaar G: The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:854-876.
26. Russo E, Citraro R, Scicchitano F, Urzino A, Marra R, Rispoli V, De Sarro G: Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav Brain Res 2011, 225:373-376.
27. Jobe PC, Browning RA: The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 2005, 7:602-619. (Pubitemid 43013007)
28. Sarkisova KY, Kuznetsova GD, Kulikov MA, van Luijtelaar G: Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms. Epilepsia 2010, 51:146-160.
29. Russo E, Citraro R, Scicchitano F, De Fazio S, Perrotta I, Di Paola ED, Constanti A, De Sarro G: Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011, 52:1341-1350.
30. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S: Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344. (Pubitemid 350243401)
31. Denning DG, Conwell Y, King D, Cox C: Method choice, intent, and gender in completed suicide. Suicide Life Threat Behav 2000, 30:282-288.
32. Frye CA: Hormonal influences on seizures: basic neurobiology. Int Rev Neurobiol 2008, 83:27-77.
33. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M: Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998, 83:2099-2103. (Pubitemid 28496343)
34. Veliskova J, Claudio OI, Galanopoulou AS, Lado FA, Ravizza T, Velisek L, Moshe SL: Seizures in the developing brain. Epilepsia 2004, 45(Suppl 8):6-12. (Pubitemid 39648261)
35. Giorgi FS, Veliskova J, Chudomel O, Kyrozis A, Moshe SL: The role of substantia nigra pars reticulata in modulating clonic seizures is determined by testosterone levels during the immediate postnatal period. Neurobiol Dis 2007, 25:73-79. (Pubitemid 44765218)
36. Molsa PK, Marttila RJ, Rinne UK: Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995, 91:159-164.
37. Barron AM, Pike CJ: Sex hormones, aging, and Alzheimer's disease. Front Biosci (Elite Ed) 2012, 4:976-997.
38. Lopez OL, Becker JT, Kuller LH: Patterns of Compensation and Vulnerability in Normal Subjects at Risk of Alzheimer's Disease. J Alzheimers Dis 2012, 33(Suppl 1):427-38.
39. Lopez OL: The growing burden of Alzheimer's disease. Am J Manag Care 2011, 17(Suppl 13):S339-S345.
40. Dye RV, Miller KJ, Singer EJ, Levine AJ: Hormone replacement therapy and risk for neurodegenerative diseases. Int J Alzheimers Dis 2012, 2012:258454.
41. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC: Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 2001, 158:1173-1177. (Pubitemid 32221809)
42. Lee HB, Lyketsos CG: Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry 2003, 54:353-362. (Pubitemid 37270616)
43. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S: Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002, 288:1475-1483.
44. Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Morales RR, Frajese GV, Swaab DF: Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. Neurobiol Aging 2011, 32:1964-1976.
45. Carlson LE, Sherwin BB, Chertkow HM: Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer's disease patients compared to healthy controls. Horm Behav 1999, 35:254-263. (Pubitemid 29287841)
46. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM: Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis 2007, 28:76-82. (Pubitemid 47429975)
47. Long J, He P, Shen Y, Li R: New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptorbeta. J Alzheimers Dis 2012, 30:545-558.
48. Mayberg HS: Clinical correlates of PET-and SPECT-identified defects in dementia. J Clin Psychiatry 1994, 55(Suppl):12-21. (Pubitemid 24381129)
49. Caroli A, Geroldi C, Nobili F, Barnden LR, Guerra UP, Bonetti M, Frisoni GB: Functional compensation in incipient Alzheimer's disease. Neurobiol Aging 2010, 31:387-397.
50. Seigel R, Naishadham D, Jemal A: Cancer Statistics 2012. CA Cancer J Clin 2012, 62:10-29.
51. Cousins JP, Harper G: Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression. Cancer Lett 1996, 110:163-167. (Pubitemid 27042936)
52. Gawrysiak MJ, Carvalho JP, Rogers BP, Nicholas CR, Dougherty JH, Hopko DR: Neural Changes following Behavioral Activation for a Depressed Breast Cancer Patient: A Functional MRI Case Study. Case reports in psychiatry 2012, 2012:152916.
53. Spiegel D, Giese-Davis J: Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003, 54:269-282. (Pubitemid 37267857)
54. Evans DL, McCartney CF, Nemeroff CB, Raft D, Quade D, Golden RN, Haggerty JJ Jr, Holmes V, Simon JS, Droba M, et al: Depression in women treated for gynecological cancer: clinical and neuroendocrine assessment. Am J Psychiatry 1986, 143:447-452. (Pubitemid 16119749)
55. Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH: Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1242-1247. (Pubitemid 47081310)
56. Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, Neri E, Taylor CB, Kraemer HC, Spiegel D: Depression and stress reactivity in metastatic breast cancer. Psychosom Med 2006, 68:675-683. (Pubitemid 44454635)
57. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001, 158:1252-1257. (Pubitemid 32717699)
58. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R: Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998, 90:30-36. (Pubitemid 28078078)
59. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7:468-473. (Pubitemid 34712898)
60. Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18:2143-2151. (Pubitemid 30324368)
61. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-23. (Pubitemid 40321763)
62. Miller AH, Pariante CM, Pearce BD: Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999, 461:107-116.
63. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, Miller AH: The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999, 140:4359-4366. (Pubitemid 30647135)
64. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T: Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000, 10:129-132. (Pubitemid 30120043)
65. Lestage J, Verrier D, Palin K, Dantzer R: The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 2002, 16:596-601. (Pubitemid 35333740)
66. DiMatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107. (Pubitemid 30482715)
67. Pinquart M, Duberstein PR: Depression and cancer mortality: a meta-analysis. Psychol Med 2010, 40:1797-1810.
68. Sapolsky RM, Donnelly TM: Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids. Endocrinology 1985, 117:662-666.
69. Romero LM, Raley-Susman KM, Redish DM, Brooke SM, Horner HC, Sapolsky RM: Possible mechanism by which stress accelerates growth of virally derived tumors. Proc Natl Acad Sci USA 1992, 89:11084-11087.
70. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000, 6:703-706. (Pubitemid 30398797)
71. Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007, 21:374-383. (Pubitemid 46528684)
72. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001, 15:199-226. (Pubitemid 33070955)
73. Linden W, Vodermaier A, Mackenzie R, Greig D: Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age. J Affect Disord 2012, 141:343-351.
74. Hopwood P, Stephens RJ: Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000, 18:893-903. (Pubitemid 30106622)
75. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000, 83:447-453. (Pubitemid 30487855)
76. Miller S, Lo C, Gagliese L, Hales S, Rydall A, Zimmermann C, Li M, Rodin G: Patterns of depression in cancer patients: an indirect test of genderspecific vulnerabilities to depression. Soc Psychiatry Psychiatr Epidemiol 2011, 46:767-774.
77. Pud D: Gender differences in predicting quality of life in cancer patients with pain. Eur J Oncol Nurs 2011, 15:486-491.
78. Duffy LS, Greenberg DB, Younger J, Ferraro MG: Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 1999, 40:304-308. (Pubitemid 29315950)
79. Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH: Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1993, 27:277-281.
80. Day R: Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 2001, 949:143-150. (Pubitemid 34059970)
81. Day R, Ganz PA, Costantino JP: Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 2001, 93:1615-1623. (Pubitemid 33094868)
82. Banos G, Guarner V, Perez-Torres I: Sex steroid hormones, cardiovascular diseases and the metabolic syndrome. Cardiovasc Hematol Agents Med Chem 2011, 9:137-146.
83. Pavlovic AM, Pekmezovic T, Zidverc-Trajkovic J, Jovanovic Z, Mijajlovic M, Pavlovic D, Tomic G, Sternic N: What are the differences between younger and older patients with symptomatic small vessel disease? Clin Neurol Neurosurg 2011, 113:762-767.
84. Steiner M: Serotonin, depression, and cardiovascular disease: sex-specific issues. Acta Physiol (Oxf) 2011, 203:253-258.
85. Vitale C, Miceli M, Rosano GM: Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric 2007, 10(Suppl 2):16-20. (Pubitemid 47450853)
86. Reckelhoff JF: Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 2005, 45:170-174. (Pubitemid 40179952)
87. Plante GE: Depression and cardiovascular disease: a reciprocal relationship. Metabolism 2005, 54:45-48. (Pubitemid 40546023)
88. Lombard JH: Depression, psychological stress, vascular dysfunction, and cardiovascular disease: thinking outside the barrel. J Appl Physiol 2010, 108:1025-1026.
89. Blazer DG 2nd, Hybels CF: Origins of depression in later life. Psychol Med 2005, 35:1241-1252. (Pubitemid 41264304)
90. Kales HC, Maixner DF, Mellow AM: Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry 2005, 13:88-98. (Pubitemid 41031097)
91. Whyte EM, Mulsant BH, Vanderbilt J, Dodge HH, Ganguli M: Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc 2004, 52:774-778. (Pubitemid 38596498)
92. Milot MR, Plamondon H: Changes in HPA reactivity and noradrenergic functions regulate spatial memory impairments at delayed time intervals following cerebral ischemia. Horm Behav 2011, 59:594-604.
93. Fang J, Cheng Q: Etiological mechanisms of post-stroke depression: a review. Neurol Res 2009, 31:904-909.
94. Hakim AM: Depression, strokes and dementia: new biological insights into an unfortunate pathway. Cardiovasc Psychiatry Neurol 2011, 2011:649629.
95. Spalletta G, Bossu P, Ciaramella A, Bria P, Caltagirone C, Robinson RG: The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006, 11:984-991. (Pubitemid 44631641)
96. Tiemeier H, Bakker SL, Hofman A, Koudstaal PJ, Breteler MM: Cerebral haemodynamics and depression in the elderly. J Neurol Neurosurg Psychiatry 2002, 73:34-39. (Pubitemid 34713009)
97. Galynker II, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D: Hypofrontality and negative symptoms in major depressive disorder. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1998, 39:608-612. (Pubitemid 28175832)
98. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR Jr, et al: Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp 2009, 30:2766-2788.
99. Videbech P: PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand 2000, 101:11-20. (Pubitemid 30041119)
100. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, et al: Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994, 44:1246-1252. (Pubitemid 24232223)
101. Herrmann LL, Le Masurier M, Ebmeier KP: White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry 2008, 79:619-624. (Pubitemid 351829430)
102. Godin O, Dufouil C, Maillard P, Delcroix N, Mazoyer B, Crivello F, Alperovitch A, Tzourio C: White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. Biol Psychiatry 2008, 63:663-669. (Pubitemid 351329279)
103. Soennesyn H, Oppedal K, Greve OJ, Fritze F, Auestad BH, Nore SP, Beyer MK, Aarsland D: White matter hyperintensities and the course of depressive symptoms in elderly people with mild dementia. Dementia and geriatric cognitive disorders extra 2012, 2:97-111.
104. Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, Nierenberg AA, Fava M: Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. J Nerv Ment Dis 2007, 195:175-178.
105. Ahearn EP, Jamison KR, Steffens DC, Cassidy F, Provenzale JM, Lehman A, Weisler RH, Carroll BJ, Krishnan KR: MRI correlates of suicide attempt history in unipolar depression. Biol Psychiatry 2001, 50:266-270. (Pubitemid 32778443)
106. Amore M, Innamorati M, Costi S, Sher L, Girardi P, Pompili M: Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol 2012, 2012:280724.
107. Seidman SN, Araujo AB, Roose SP, McKinlay JB: Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry 2001, 50:371-376. (Pubitemid 32816951)
108. Ceretta LB, Reus GZ, Abelaira HM, Jornada LK, Schwalm MT, Hoepers NJ, Tomazzi CD, Gulbis KG, Ceretta RA, Quevedo J: Increased prevalence of mood disorders and suicidal ideation in type 2 diabetic patients. Acta Diabetol 2012, 49(Suppl 1):S227-34.
109. Bourke C, Harrell CS, Neigh GN: Stress-induced sex differences: Adaptations mediated by the glucocorticoid receptor. Horm Behav 2012, 62:210-8.
110. Cahill L: His brain, her brain. Sci Am 2005, 292:40-47. (Pubitemid 40642913)
111. Campbell T, Lin S, DeVries C, Lambert K: Coping strategies in male and female rats exposed to multiple stressors. Physiol Behav 2003, 78:495-504. (Pubitemid 36369722)
112. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652. (Pubitemid 34260983)
113. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56. (Pubitemid 350295688)